Distinct chromatin binding patterns for estrogen receptor and histone marks classify aromatase inhibitor resistant breast cancer

被引：0
|
作者：
Jansen, M. [1 ]
Knijnenburg, T. [2 ]
Reijm, E. [3 ]
Simon, I. [4 ]
Kerkhoven, R. [5 ]
Alexi, X. [2 ]
Wessels, L. [2 ]
Linn, S. [2 ]
Berns, P. [3 ]
Zwart, W. [2 ]
机构：
[1] Erasmus MC Univ, Med Ctr Rotterdam, Rotterdam, Netherlands
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Erasmus MC Univ, Med Ctr, Rotterdam, Netherlands
[4] Agendia, Amsterdam, Netherlands
[5] Netherlands Canc Inst, Cent Genom Facil, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
500
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [31] Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third generation aromatase inhibitor vorozole
    de Jong, PC
    van de Ven, J
    Nortier, JWR
    Maitimu-Smeele, I
    Donker, GH
    Thijssen, JHH
    Slee, PHTJ
    Blankenstein, MA
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S5 - S5
  • [32] Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
    Achinger-Kawecka, Joanna
    Valdes-Mora, Fatima
    Luu, Phuc-Loi
    Giles, Katherine A.
    Caldon, C. Elizabeth
    Qu, Wenjia
    Nair, Shalima
    Soto, Sebastian
    Locke, Warwick J.
    Yeo-Teh, Nicole S.
    Gould, Cathryn M.
    Du, Qian
    Smith, Grady C.
    Ramos, Irene R.
    Fernandez, Kristine F.
    Hoon, Dave S.
    Gee, Julia M. W.
    Stirzaker, Clare
    Clark, Susan J.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [33] Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
    Joanna Achinger-Kawecka
    Fatima Valdes-Mora
    Phuc-Loi Luu
    Katherine A. Giles
    C. Elizabeth Caldon
    Wenjia Qu
    Shalima Nair
    Sebastian Soto
    Warwick J. Locke
    Nicole S. Yeo-Teh
    Cathryn M. Gould
    Qian Du
    Grady C. Smith
    Irene R. Ramos
    Kristine F. Fernandez
    Dave S. Hoon
    Julia M. W. Gee
    Clare Stirzaker
    Susan J. Clark
    Nature Communications, 11
  • [34] Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer
    DeMichele, A. M.
    Clark, A. S.
    Holmes, R.
    Volpe, M.
    Medrano, C.
    Troxel, A.
    Fox, K.
    Domchek, S.
    Matro, J.
    Bradbury, A.
    Shih, N.
    Feldman, M.
    Hexner, E.
    Bromberg, J.
    CANCER RESEARCH, 2017, 77
  • [35] RRHGE: A Novel Approach to Classify the Estrogen Receptor Based Breast Cancer Subtypes
    Saini, Ashish
    Hou, Jingyu
    Zhou, Wanlei
    SCIENTIFIC WORLD JOURNAL, 2014,
  • [36] Low Estrogen Receptor Positive Breast Cancer: Is This a Distinct Group?
    Gloyeske, N. C.
    Dabbs, D. J.
    Mallon, A.
    Bhargava, R.
    MODERN PATHOLOGY, 2013, 26 : 44A - 44A
  • [37] Low Estrogen Receptor Positive Breast Cancer: Is This a Distinct Group?
    Gloyeske, N. C.
    Dabbs, D. J.
    Mallon, A.
    Bhargava, R.
    LABORATORY INVESTIGATION, 2013, 93 : 44A - 44A
  • [38] Preclinical evaluation of estrogen receptor coregulator binding inhibitor ERX-245 in breast cancer
    Viswanadhapalli, Suryavathi
    Ma, Shihong
    Lee, Tae Kyung
    Liu, Xihui
    Kassees, Kara
    Pratap, Uday P.
    Liu, Junhao
    Tang, Weiwei
    Tekmal, Rajeshwar R.
    Ahn, Jung-Mo
    Raj, Ganesh, V
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2020, 80 (16)
  • [39] Whole genome comparisons of pre- and post-aromatase inhibitor treatment in estrogen receptor positive breast cancer
    Ellis, Matthew J.
    Lie, Ding
    Shen, Dong
    Luo, Jingqin
    Suman, Vera J.
    Wallis, John W.
    Van Tine, Brian A.
    Hoog, Jeremy
    Crowder, Robert J.
    Snider, Jacqueline E.
    Ballman, Karla
    Chen, Ken
    Koboldt, Daniel C.
    Schierding, William S.
    McMichael, Joshua F.
    Miller, Christopher A.
    Kandoth, Cyriac
    Lu, Charles
    Harris, Christopher C.
    McLellan, Michael D.
    Wendl, Michael C.
    DeSchryver, Katherine
    Allred, D. Craig
    Esserman, Laura
    Unzeitig, Gary
    Margenthaler, Julie
    Babiera, G. V.
    Marcom, P. Kelly
    Guenther, J. M.
    Leitch, Marilyn
    Hunt, Kelly
    Olson, John
    Tao, Yu
    Fulton, Lucinda L.
    Fulton, Robert S.
    Harrison, Michelle
    Oberkfell, Ben
    Du, Feiyu
    Demeter, Ryan
    Griffith, Malachi
    Vickery, Tammi L.
    McDonald, Sandra A.
    Watson, Mark
    Dooling, David J.
    Ota, David
    Chang, Li-Wei
    Bose, Ron
    Ley, Timothy J.
    Wilson, Richard K.
    Mardis, Elaine R.
    CANCER RESEARCH, 2012, 72
  • [40] Progesterone receptor levels are associated with time to aromatase inhibitor treatment failure in estrogen receptor-positive advanced breast cancer.
    Cristofanilli, M.
    De Giorgi, U.
    Rohren, E.
    Ueno, N. T.
    Miller, C.
    Doyle, G., V
    Jackson, S.
    Andreopoulou, E.
    Handy, B. C.
    Reuben, J. M.
    Hortobagyi, G. N.
    Macapinlac, H. A.
    Fritsche, H. A.
    Valero, V.
    CANCER RESEARCH, 2009, 69 (02) : 362S - 362S
12345